Azienda Ospedaliera S.Giuseppe Moscati

Real‐world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Summary Venetoclax (VEN) plus hypomethylating agents (HMAs) represents the standard of care for newly diagnosed acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy, but prospective real‐world observational data outside randomized clinical trials remain limited...

Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee

Abstract Hematopoietic cell transplantation, cellular and gene therapies, and (CAR)-T cells have revolutionized outcomes in hematologic disorders. However, major disparities persist in their availability, accessibility, and affordability, particularly in low- and middle-income co...

Lumbar Plexus Disorders Presenting as Low Back Pain: A Narrative Review of a Practical Diagnostic Imaging Approach

Low back pain (LBP) is one of the most common causes of medical consultation worldwide and is typically attributed to degenerative spinal disorders. However, a subset of patients presents with LBP related to extra-spinal conditions, including disorders of the lumbar plexus. These...